Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 26Genitourinary 16Plasma cell 10Thoracic 4Gastrointestinal 4Sarcoma 3Head & Neck 3Other solid neoplasm 2Lymphoid 2Gynecologic 2Endocrine 2Dermatologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1

Conditions

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Ovarian Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Denosumab × Gynecologic × Clear all
NCT06513624 2025-07-25

ETC-159-02

National University Hospital, Singapore

Phase 1 Recruiting
16 enrolled
Gynecologic

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

NCT03382574 2022-06-14

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Terminated
2 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡